CCXI Shares Outstanding History
Below is a table of the CCXI shares outstanding history going back to 2/8/2012:

Date CCXI Shares Outstanding
2/8/201234.02M
3/15/201236.16M
5/4/201236.17M
8/3/201236.17M
11/8/201236.27M
3/7/201336.77M
5/6/201342.62M
8/5/201342.84M
11/4/201342.87M
3/7/201443.15M
5/1/201443.25M
8/1/201443.34M
10/31/201443.34M
3/6/201543.54M
5/1/201543.69M
8/3/201544.07M
11/4/201544.13M
3/4/201644.29M
4/29/201644.29M
7/29/201647.76M
10/31/201647.81M
3/3/201748.15M
4/28/201748.17M
7/31/201748.71M
10/31/201748.77M
2/28/201848.92M
4/30/201849.15M
7/31/201850.38M
10/31/201850.53M
2/28/201952.57M
4/30/201958.05M
7/31/201958.25M
8/11/201439.17M
10/31/201958.27M
2/28/202061.64M
4/30/202061.85M
7/31/202068.89M
10/31/202069.21M
2/22/202169.61M
4/23/202169.75M
7/30/202169.90M
10/29/202170.03M
2/22/202270.84M
4/29/202271.19M
7/29/202271.36M

Also see: CCXI Market Cap History
CCXI YTD Return
CCXI Historical Shares Outstanding:
+7.33% CAGR
CCXI Historical Shares Outstanding: +7.33% CAGR

Mouse over chart for data details
2/8/2012 ...7/29/2022
ChemoCentryx is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. Co. targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the U.S., Co. markets TAVNEOS® (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis, and microscopic polyangiitis. Co. is also developing TAVNEOS for the treatment of severe Hidradenitis Suppurativa. We show 45 historical shares outstanding datapoints in our coverage of CCXI's shares outstanding history.

Understanding the changing numbers of CCXI shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CCXI versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CCXI by allowing them to research CCXI shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree CCXI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
ChemoCentryx (CCXI) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CDAK Shares Outstanding History
CDMO Shares Outstanding History
CDNA Shares Outstanding History
CDRE Shares Outstanding History
CDTX Shares Outstanding History
CDXC Shares Outstanding History
CELC Shares Outstanding History
CELG Shares Outstanding History
CELZ Shares Outstanding History
CEMI Shares Outstanding History
More Healthcare companies »

 

CCXI Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.